

Prevention & Treatment of Hepatitis and Chronic Liver Disease

Washington, DC April 22, 2023

Conference Location	Embassy Suites – Chevy Chase Pavilion 4300 Military Rd NW Washington, DC 20015 (202) 362-9300	https://www.hilton.com/en/hotels/wasches-embassy-suites-washington-dc-chevy-chase-pavilion
----------------------------	---	---

Parking at the Conference	A reduced rate has been arranged for self-parking during the program
----------------------------------	--

Driving Directions	The hotel is located near the corner of Wisconsin Avenue NW and Military Road, NW. The Embassy Suites is just adjacent to the Friendship Heights Metro Station (Red Line).
---------------------------	--

Seminar Agenda and Syllabus Information	Registration begins at 7:30 a.m. in the Chevy Chase Ballroom The Hepatitis and Chronic Liver Disease seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet or personal computer. Instructions to download the <i>App</i> will be provided. Wi-Fi will be available
--	---

Pre-Program Activities	Pre-Lecture 1 – Viral Hepatitis –A summary for discovery and natural history of HCV 60 min Pre-Lecture 2 - End Stage Liver Disease: An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process – 45 min
7:30 am	<i>Registration and View Exhibits</i>
8:00 am	Opening Comments and Pre-Test
8:20 am	Review of Viral Hepatitis –HCV <ul style="list-style-type: none"> • Highlight of Pre-Lecture 1 • Screening and Treatment of HCV Clinical Cases and Discussion
9:00 am	Hepatitis B: Epidemiology, Natural History and Treatment <ul style="list-style-type: none"> • The epidemiology of the Hepatitis B infection • Efficacies and opportunities in HBV testing and vaccination • Anti-viral therapies of HBV • The growing relationship between HBV and HDV
9:30 am	<i>Product Theater # 1 Break and View exhibits</i>
10:10 am	Delta Hepatitis and Hepatitis E Update <ul style="list-style-type: none"> • Worldwide perspective and promising research studies • Real world outcome studies on HDV and HEV
10:45 am	End Stage Liver Disease: Recap and Clinical Cases <ul style="list-style-type: none"> • A review of Pre-course lecture on end-stage liver disease • Clinical cases to illustrate HE and Thrombocytopenia
11:15 am	Hepatocellular Carcinoma (HCC) <ul style="list-style-type: none"> • Screening diagnostic serum assays and imaging tests • Treatment and management options: Ablation, TACE and Surgery

	•
11:45 am	Hepatocellular Carcinoma: New Systemic Treatment Options <ul style="list-style-type: none"> • A case-based approach to HCC treatment • Current FDA-Approved Therapies • New chemotherapy regimens in development and testing Immunotherapy as the new MoA for HCC
12:15 pm	<i>Luncheon and Industry Presentation #2</i>
1:00pm	<i>Dessert and View Exhibits</i>
1:10 pm	Cholestatic Liver Disease: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis (PSC) <ul style="list-style-type: none"> • Epidemiology of PSC and Ursodiol and Antibiotic Treatments • Predicting outcomes and Improving Survival in PSC patients • Causes and Markers of PBC Ursodeoxycholic Acid (UDCA) and Obeticholic Acid
1:50 pm	Alcohol Associated Liver Disease <ul style="list-style-type: none"> • The growing prevalence of alcohol over-consumption and its impact on liver health Warning signs and intervention in alcohol-associated hepatitis
2:20 pm	Fluid Management, Ascites and Hepatorenal Syndrome <ul style="list-style-type: none"> • The diagnosis and treatment of ascites • How cirrhosis can lead to portal hypertension, ascites, kidney disease and hepatorenal syndrome • New and emerging treatment approaches for of HRS
2:50 pm	<i>Break & View Exhibits</i>
3:00 pm	NAFLD and NASH <ul style="list-style-type: none"> • Epidemiology, Demographics and Diagnosis • Scoring, Staging and Management of Fatty Liver Disease • Treatment options for thrombocytopenia; including alternatives to platelet transfusion.
3:30 pm	NASH Treatments in Practice and in Development <ul style="list-style-type: none"> • Current therapies for NASH including Updates from AASLD and EASL • Lifestyle changes as a therapy Drugs in clinical development for NASH
4:10 pm	Closing Comments, Post-test and Wrap-Up Program adjourns at 4:30 pm
Post-program activities	Lecture 3 - SARS-CoV-2 and its Effect on the Liver – 45 minutes Lecture 4 - Overcoming barriers to liver health in special populations - 45 minutes

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Attendance Policies

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course's schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)**TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**CME
Information**

Nurses - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-22-1264. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)TM organizations accredited by ACCME.

**COLEMAN SMITH, MD**

Dr. Smith received his medical degree from the University of Sydney, Australia and subsequently completed his internal medicine and gastroenterology training at that institution. He went on to spend three years at the University of Queensland in Australia where he completed a research doctoral thesis. He subsequently continued his research and clinical training in Denmark, at USC and Stanford University. He moved to Minneapolis, Minnesota in 1985 where he joined the faculty of the University of Minnesota and remained there until he moved to Georgetown University in Washington, DC in 2015. He is currently a transplant hepatologist is at the Medstar Georgetown Transplant Institute and a professor of medicine at Georgetown.

He is very actively involved in the American Association for the Study of Liver Diseases and has served on a number of committees including on the executive committee of the Clinical Practice Special Interest Group. He was the founding chairman of the Mid West branch of the American Liver Foundation and is currently a member of the National Medical Advisory Board of the American Liver Foundation.

**KIRTI SHETTY, MD, FACC**

Dr. Kirti Shetty is currently Professor of Medicine at the University of Maryland School of Medicine and Adjunct Professor of Medicine and Surgery at Georgetown University. She serves as the Director of Hepatology at the University of Maryland. Her clinical interests include viral hepatitis, nonalcoholic fatty liver disease, liver cancer and liver transplantation outcomes. Dr. Shetty's research focuses on mechanisms of hepatocarcinogenesis in cirrhosis. Her ongoing translational research collaborations explore biomarkers for hepatocellular carcinoma and chemopreventive approaches in patients with cirrhosis.

Dr. Shetty has authored numerous publications in prestigious journals and has both contributed to and edited textbooks in liver disease. She attained her medical degree at

Christian Medical College in Vellore, India.

**ANDREA KELLER, PA-C, MSc**

Andréa L. Keller is a board-certified Physician Assistant. She has a Bachelor of Science degree in Biology/Pre-Med from St. John Fisher College in Rochester, NY as well as her Master of Science degree in Physician Assistant Studies from Daemen University in Amherst, NY. She started working in Hepatology late 2010 with Metropolitan Liver Diseases/Gastroenterology Center continuing into her current and latest role with MedStar Georgetown Transplant Institute in early 2014. She provides care for numerous hepatologic diseases and conditions preparing those for transplant and then caring for them once transplanted, she is a current and upstanding member of the AAPA, AASLD, GHAPP and CLDF. Andréa is responsible for managing,

diagnosing, treating and aiding in the preventative management of all MedStar Georgetown transplant patients alongside her colleagues. She is the main provider offering care to our Northern Virginia patients.

**Your
Seminar
Faculty**

